P, PROSTATE CANCER UK ANNUAL REPORT AND FINANCIAL STATEMENTS 2022/23 ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## |As a result ofthe above, the Trus
test.|tee|s consider that Prostate Cancer UK satisfies the||public|benefit| |---|---|---|---|---|---| |Principal
risks and uncertainties|||||| |The principal
risks to which the charity is exposed, as identified
by the Trustees, are|||regularly||| |reviewed
and systems
have been|established
to mitigate them. A risk register summarises||||the| |principal
risks facing the charity, graded according to their likelihood
and impact, and||||identifies|| |actions to manage them. The register has been redesigned
to align with the new organisational|||||| |strategy,
with individual
risks and|their mitigations
set out under one overall
risk and||each ofthe||| |Pillars and Drivers.
It is reviewed|and updated
by the Leadership
Team each month,|||and reviewed|| |twice a year by the Finance, Risk|and Audit Committee.
The Board of Trustees reviews the||||register| |annually,
but any 'red light' issues|are brought
to their attention as they arise.||||| |Pillar
1 - That we fail to|~|We will develop specific messaging
and training||for|| |reach and activate more||volunteers
based on their geographical
location|||| |men into making
an|~|We will use data and evidence available
to us to|||| |informed
choice about their||triangulate
to those areas most in need|||| |prostate cancer risk||We will ensure that any insights we gather are|||| |||communicated
in a clear and helpful way.|||| |Pillar 2 —That we fail to|~|We will have clear action plans and measurement||for|| |reduce health
inequalities||each commitment|||| ||~|We are having
honest and open conversations|within||| |||Black communities|||| ||~|We will deploy targeted
programmes
ofactivity.|||| |Pillar 3—That we fail to|~|We will issue clear guidance
around
the funding||process|| |accelerate earlier||to ensure applications
are of high quality and ready to|||| |diagnosis
and the delivery||fund.|||| |of better, more precise|||||| |iraairnani.|||||| |||||We will develop
compelling
case studies that emphasise|We will develop
compelling
case studies that emphasise| |---|---|---|---|---|---| |||||the importance
and impact ofresearch to inspire|| |||||audiences|| |||||We will work with partners
to ensure that early diagnosis|| |||||trials and programmes
are fully funded.|| |Pillar 4 —That we fail to||||We will increase the provision
of individual
and group|| |transform||the experience||clinical supervision|| |and support for|||men with|We will improve
accessibility to our services|| |prostate cancer|||to live and|We will innovate
and improve
our processes
in line with|| |die well||||feedback to improve the services we offer.|| |Driver|1 —That||trust
in our|Trust in our brand remains
high|| |brand|comes into disrepute|||Key stakeholder
relationships
will be fully vetted to|| |||||ensure they align with our values|| |||||Our fundraisers
are inducted
into the Institute of Funding|| |||||code ofpractice|| |||||Risks assessments
and health
and safety plans are put|| |||||in place ahead ofany event we' re involved
with.|| |Driver|2 —That||we fail to|We will use data, analysis
and insight to drive our|| |generate||sufficient income||decision
making|| |to fund our activities||||We are investing
for growth
in areas that are new to|us| |||||We will ensure we' re maximising
all revenue
streams|| |||||We will generate
net income growth
through
strong cost|| |||||and margin
controls|| |||||We will innovate
the products we offer to ensure we|| |||||engage
with a wide ranging
audience for longer.|| |Driver|3—That||we are|We have strong
mitigation
plans
in place to manage|| |unable|to recruit||or retain|adverse
risks across retention,
recruitment,
inclusion,|| |staff||||health and safety and safeguarding|| |||||We have developed
an EDI plan and set up People|| |||||Networks
to engage
with staff and promote
diversity|and| |||||inclusion across our organisation|| |||||We have introduced
a new pay framework
and hybrid|| |||||working
policy to attract candidates
and to ensure staff|| |||||are remunerated
in line with the market average.|| |Driver|4 —That||we are|We have an insight strategy and data strategy
which|is| |unable|to use the data and|||reviewed
quarterly
by the leadership
team|| |insight|available||to us to|A roadmap
and best practices have been introduced|and| |make|accurate||decisions|are regularly
reviewed.|| ## ## ## ## ## ## ## ## ## ## ## ## ||||Unrestricted|Restricted|Total|Total| |---|---|---|---|---|---|---| ||||Funds|Funds|2023|2022| |||Notes|K'000|K'000|K'000|E'000| |INCOME FROM||||||| |Donations
and legacies|||28,687|3,999|32,686|34,951| |Other trading
activities|||541||541|419| |Investments
—bank|interest||722||722|73| |Total|||29950|3,999|33949|35,443| |EXPENDITURE ON||||||| |Raising funds|||9,420||9,420|9,375| |Charitable
activities|||22,415|2,506|24,921|15,685| |Total|||31,835|2,506|34,341|25,060| |Net income/(expenditure)||4|(1,885)|1,493|(392)|10,383| |Transfers
between
funds||18|3,224|(3,224)||| |Net movement
in funds|||1,339|(1,731)|(392)|10,383| |Reconciliation
offunds:||||||| |Total funds brought|forward||27,142|9,196|36,338|25,955| |Total funds carried|forward|'l8|28,481|7,465|35,946|36,338| ## |||||Unrestricted|Restricted|Total|Total| |---|---|---|---|---|---|---|---| |||||Funds|Funds|2023|2022| |||||R'000|R'000|R'000|R'000| |INCOME FROM|||||||| |Donations
and|legacies|||28,964|3,999|32,963|35,136| |Investments||||722||722|73| |Total||||29,686|3,999|33,685|35,209| |EXPENDITURE|ON||||||| |Raising funds||||9,160||9,160|9,144| |Charitable
activities||||22,411|2,506|24,917|15,682| |Total||||31,571|2,506|34,077|24,826| |Net income/(expenditure)||||(1,885)|1,493|(392)|10,383| |Transfers
between||funds||3,224|(3,224)||| |Net movement|in funds|||1,339|(1,731)|(392)|10,383| |Reconciliation|of|funds:|||||| |Total funds brought|||forward|27,142|9,196|36,338|25,955| |Total funds carried|||forward|28,481|7,465|35,946|36,338| ## |Balance sh|eets||as at|31 March 20|23||||| |---|---|---|---|---|---|---|---|---|---| |||||||GROUP||CHARITY|| ||||||Notes|2023|2022|2023|2022| |||||||K'000|8'000|f'000|6'000| |Fixed assets|||||||||| |Intangible
assets|||||10||9||9| |Tangible assets|||||11|120|313|120|313| |Investments|||||12||||| |Total fixed assets||||||120|322|120|322| |Current assets|||||||||| |Stocks|||||13|103|93||| |Debtors|||||14|12,099|12,751|12,192|12,891| |Short-term
deposits||||||25,894|20,589|25,894|20,589| |Cash at bank|and|in|hand|||19,534|23,355|19,470|23,266| |Total current|assets|||||57,630|56,788|57,556|56,746| |Liabilities:|||||||||| |Creditors: Amounts|||falling|due within one|15|9,751|11,734|9,677|11,692| |year|||||||||| |Net current assets||||||47,879|45,054|47,879|45,054| |Total assets|less|current||liabilities||47,999|45,376|47,999|45,376| |Creditors: Amounts|||falling|due after more|||||| |than one year|||||16|12,053|9,038|12,053|9,038| |Net assets||||||35,946|36,338|35,946|36,338| |Funds:|||||||||| |Restricted
income|||funds||18|7,465|9,196|7,465|9,196| |Unrestricted|funds||||||||| |General|||||18|28,361|23,449|28,361|23,449| |Designated|||||18|120|3,693|120|3,693| |||||||28,481|27,142|28,481|27,142| |Total funds||||||35,946|36,338|35,946|36,338| ||||||2023|2023|2022|2022| |---|---|---|---|---|---|---|---|---| |||||Notes|8'000|6'000|R'000|R'000| |Cash flows from operating||activities:||||||| |Net cash|provided
by (used in) operating|||||||| |activities||||22||762||9,456| |Cash flows from investing||activities:||||||| |Interest|||||722||73|| |Purchase|offixed assets||||||(40)|| |Net cash
activities|provided
by (used in) investing|||||722||33| |Change
in cash and cash||equivalents|in|||1,484||9,489| |the reporting
period||||||||| |Cash and
beginning|cash equivalents
ofthe reporting|at the
period||||43,944||34,455| |Cash and cash equivalents
the reporting
period||at the end|of|||45,428||43,944| |Changes|in net debt:|||||||| |Cash and|cash equivalents|at start ofyear||||||43,944| |Cash flows||||||||1,484| |Cash and|cash equivalents|at end ofyear||||||45,428| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ||||||Income|Income|||2023|202| |---|---|---|---|---|---|---|---|---|---|---| ||||||Unrestricted|Restricted||Total|income|Total| ||||||R'000||6'000||8'000|R'000| |Individual|donors and legacies||||16,105||61||16,166|16,006| |Community||and events|||10,232||||10,232|12,323| |Corporate|donors||||1,487||305||1,792|2,469| |Major donors and charitable|||trusts||781||1,183||1,964|1,671| |Donated|goods and services||||82||||82|73| |Government||grants|||||2,450||2,450|2,409| ||||||28,687||3,999||32,686|34,951| |Ofwhich|in|2022:||||||||| |Restricted||||||||||4,217| |Unrestricted||||||||||30,734| |||||||||||34,951| |The income||from government||grants|relates to E2,450k||from the|Medical Research||Council| |for research||(2022:E509k), the||NHS|Risk Checker Campaign
ANIL (2022:E1,899k),|||||and the| |Coronavirus||Job Retention Scheme|||ANIL (2022:f1k).|||||| ||||||Expenditure|on||||| ||||||raising funds||||2023|2022| ||||||Direct|Support|||Total|Total| ||||||costs||costs||costs|costs| ||||||R'000||R.'000||R'000|R'000| |Individual|donors and legacies||||4,713||735||5,448|5,703| |Community||and events|||2,324||362||2,686|2,270| |Corporate|donors||||598||93||691|758| |Major donors and charitable|||trusts||319||50||369|444| |Trading|||||226||||226|200| ||||||8,180||1,240||9,420|9,375| ## ||||||2023|2022| |---|---|---|---|---|---|---| ||||||Total|Total| ||||||R'000|8'000| |Turnover|||||541|419| |Cost ofgoods|sold||||(260)|(219)| |Gross profit|||||281|200| |Administrative|expenses||||(148)|(168)| |Net profit|||||133|32| |Income transferred||by Gift Aid|||(133)|(32)| |Retained
in subsidiary||||||| ||||||2023|2022| ||||||Total|Total| ||||||F'000|E'000| |Total current assets||as at 31 March|||295|248| |Total
current|liabilities
as||at|31|(295)|(248)| |March||||||| |Net assets held as||at 31 March||||| ## |4 Net income for the year|4 Net income for the year|4 Net income for the year||| |---|---|---|---|---| |This is stated after charging:||||| ||||2023|2022| ||||R'000|f'000| |Depreciation
and amortisation|||202|261| |Auditor's|remuneration|—audit services|39|34| |Auditor's|remuneration|—other services|4|4| |Operating|lease rentals|—property|461|510| ## |5 Charitable
activities||||| |---|---|---|---|---| ||||2023|2022| ||Direct|Support|Total costs|Total| ||costs|costs||| ||R'000|R'000||R'000| |Research|9,991|259|10,250|1,528| |Support and influencing|3,128|1,273|4,401|3,539| |Awareness|7,788|2,482|10,270|10,618| ||20,907|4,014|24,921|15,685| ## |6 Grants awarded|6 Grants awarded|||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---| |Grant
commitments||comprise|research||commitments||||and|programme|commitments.|| |Research|grants are awarded||to fund|researchers|||in|the|key areas of better||treatment|and| |better diagnosis
in line||with our|Research strategy.|||||||||| ||||2023|||2022||||||| ||||Total|||Total||Better||Better|Smarter|| |||||||||Treatment||Diagnosis|Data|| |Research|grants were|awarded|R'000|||R'000||||||| |to the following
institutions:||||||||||||| |||||2,550||||||||| |Imperial
College London||||||||||||| |Institute ofCancer Research||||2,013||128||||||| |University|ofGlasgow|||1,749||||||||| |University|College London|||690||||||||| |Newcastle|University|||513||||||||| |University|ofSheffield|||447||||||||| |Swansea|University|||402||||||||| |University|ofOxford|||299||||||||| |University|ofEast Anglia|||292||||||||| |University|of Nottingham|||259||||||||| |University|of Bristol|||245||||||||| |University|of Manchester|||118||546||||||| |Queen's|University
Belfast|||||284||||||| |||||9,577||958||||||| ## ## |||||2023|2022| |---|---|---|---|---|---| |Reconciliation|of|research grants payable:||R'000|E'000| |Commitments|at 1|April||16,544|20,318| |Commitments|made
in the year|||9,577|958| |Grant adjustments||and cancellations||(226)|(115)| |Grants paid during||the year||(5,509)|(4,617)| |Commitments|at|31 March||20,386|16,544| |||||2023|2022| |Outstanding|research commitments||at 31 March are payable|f'000|E'000| |as follows:|||||| |Within one year (Note 15)||||8,333|7,531| |After more than one year (Note 16)||||12,053|9,013| |||||20 386|16,544| |||||2023|2022| |---|---|---|---|---|---| |Reconciliation|of|programme|grants payable:|K'000|K'000| |Commitments|at 1|April|||12| |Commitments|made
in the year||||| |Grant adjustments||and cancellations|||(3)| |Grants paid during||the year|||(9)| |Commitments|at 31 March||||| |The average
full-time
equi
was:|valent
number
of persons
employ|ed
by the group
duri|ng
the y| |---|---|---|---| |||2023|2022| |Fundraising||49|47| |Research||8|8| |Support and Influencing||41|36| |Communications||62|52| |Finance,
IT 8 Technology,|People and Facilities|41|38| |||201|181| |The average
number ofe
the year was as follows:|mployees
(head count based on nu|mber ofstaff employe|d)
during| |---|---|---|---| |||2023|2022| |Fundraising||52|49| |Research||8|8| |Support and Influencing||44|43| |Communications||65|54| |Finance,
IT &Technology,|People and Facilities|41|36| |||210|190| ## |nts
paid
in r|espec|t ofemployees
were:||| |---|---|---|---|---| ||||2023|2022| ||||6'000|8'000| |Salaries and|wages||8,236|6,654| |Social security costs|||893|704| |Pension costs|||946|829| |Termination|payments||45|11| |Total emoluments||ofemployees|10,120|8,198| |Agency staff|||282|172| ||||10,402|8,370| |The number ofemployees|whose emoluments|for the year were over f60,000 after salary|for the year were over f60,000 after salary| |---|---|---|---| |sacrifice was:|||| |||2023|2022| |f60,001 to 270,000||10|| |f70,001 to 280,000|||| |280,001 to F90,000|||| |f90,001 to F100,000|||| |f110,001 tof120,000|||| ## |
The breakdow|
n
of|
support co|sts and how|these are al|located
is sho|wn
below.| |---|---|---|---|---|---|---| ||||||2023|2022| ||||Raising|Charitable|Total costs|Total costs| ||||funds|activities||| ||||f.'000|R'000|R'000|| |Staff and similar|||722|2,336|3,058|| |Supplies and|services||202|656|858|802| |Premises costs|||279|903|1,182|1,139| |Depreciation|||26|86|112|160| |Governance|costs|||33|44|| ||||1,240|4,014|5,254|4,412| |Governance|costs|comprise:|||2023|2022| ||||||Total costs|Total costs| ||||||K'000|F'000| |Audit fees|||||39|34| |Trustee indemnity||insurance|||5|5| ||||||44|39| ## |10Intangible
fixed assets —Group and|Charity| |---|---| ||Software| |Cost|8'000| |At 1 April 2022|246| |Disposal|| |Additions|| |At 31 March 2023|246| |Amortisation|| |At 1 April 2022|237| |Disposal|| |Charge for the year|| |At 31 March 2023|246| |Net book value|| |Net book value at 31 March 2022|| |Net book value at 31 March 2023|| ## ||Lease|Fixtures|Computer|Computer|Total| |---|---|---|---|---|---| ||Improvements|and|equipment|and|| |||fittings|website||| ||||development||| |Cost|R'000|6'000||R'000|6'000| |At 1 April 2022|601|584||1,161|2,346| |Additions|||||| |Disposals||(50)||(470)|(520)| |At 31 March 2023|601|534||691|1,826| |Depreciation|||||| |At 1 April 2022|524|583||926|2,033| |Disposals||(50)||(470)|(520)| |Charge for the year|62|1||130|193| |At 31 March 2023|586|534||586|1,706| |Net book value|||||| |Net book value at 31 March|77|||235|313| |2022|||||| |Net book value at 31 March|15|||105|120| |2023|||||| ## ## |Group||Charity|| |---|---|---|---| |2023|2022|2023|2022| |F'000|8'000|8'000|F'000| |103|93||| ## |14Debtors||||||| |---|---|---|---|---|---|---| ||||Group||Charity|| ||||2023|2022|2023|2022| ||||R'000|R'000|R'000|R'000| |Trade debtors|||2,351|1,814|2,224|1,760| |Amounts
due from subsidiary||undertaking|||220|205| |Prepayments|||960|1,218|960|1,207| |Accrued
income|||1,449|1,633|1,449|1,633| |Other debtors|||150|158|150|158| ||||4,910|4,823|5,003|4,963| |Movember
Foundation|accrued income||7,189|7,928|7,189|7,928| |Total debtors|||12,099|12,751|12,192|12,891| ## |15Creditors —falli|ng due within o|ne year|||| |---|---|---|---|---|---| |||Group||Charity|| |||2023|2022|2023|2022| |||f'000|8'000|F'000|F'000| |Trade creditors||531|2,990|508|2,968| |Research commitments||8,333|7,531|8,333|7,531| |Other taxes and social|security|271|266|257|261| |Accruals and deferred|income|458|473|446|458| |Other creditors||158|474|133|474| |||9,751|11,734|9,677|11,692| |||||Group||Charity|| |---|---|---|---|---|---|---|---| |||||2023|2022|2023|2022| |||||8'000|8'000|F'000|F'000| |Balance|at 1 April|||9||9|| |Amounts|released|to incoming|resources|(9)||(9)|| |Amount|deferred|in the year|||||| |Balance|at 31 March||||||| |6Creditors —falling due after|more than one year|||| |---|---|---|---|---| ||Group||Charity|| ||2023|2022|2023|2022| ||8'000|8'000|E'000|E'000| |Research commitments|12,053|9,013|12,053|9,013| |Other creditors||25||25| ||12,053|9,038|12,053|9,038| |17Analysis of|group net assets|between
fu|nds||| |---|---|---|---|---|---| |||General|Designated|Restricted|Total funds| |||funds|funds|funds|| |||R'000|R'000|R'000|R'000| |Fixed assets (Note 10and 11)|||120||120| |Research designated|funds||||| |Current assets||48,345||9,285|57,630| |Liabilities due within|one year|(9,014)||(737)|(9,751)| |Liabilities due after more than one year||(10,970)||(1,083)|(12,053)| |Net assets at 31 March||28,361|120|7,465|35,946| ## |||As at|Incoming|Outgoing|Transfers|As at| |---|---|---|---|---|---|---| |||01/04/2022||||31/03/2023| |||6'000|6'000|K'000|R'000|R'000| |Restricted funds:||||||| |Movember
Foundation||6,046||(678)||5,368| |Other restricted funds:||||||| |General research||2,678|3,257|(902)|(3,009)|2,024| |Specialist Nurses Service||160|328|(488)||| |Other restricted
funds||312|414|(438)|(215)|73| |Total other restricted|funds|3,150|3,999|(1,828)|(3,224)|2,097| |Total restricted
funds||9,196|3,999|(2,506)|(3,224)|7,465| |Unrestricted
funds||23,449|29,950|(28,262)|3,224|28,361| |Designated
funds:||||||| |Fixed asset reserves||322||(202)||120| |Research designated|funds|3,371||(3,371)||| |Total designated
funds||3,693||(3,573)||120| |Total unrestricted
funds||27,142|29,950|(31,835)|3,224|28,481| |Total funds||36,338|33,949|(34,341)||35,946| |Movember|Movember
Foundation
income from its campaigns,|Movember
Foundation
income from its campaigns,| |---|---|---| |Foundation|restricted|to spend on research
and survivorship| ||services|for men with prostate cancer.| |General research|Funding|received to support either specific research| ||awards or to be put towards other unfunded|| ||research|activity.| |Specialist Nurses|Funding|for the Specialist Nurses Service to| |Service|increase|access and support for men and their| ||families|affected by prostate cancer.| ## |roup has commitments
under operating
lease
:|s due within the periods stated|| |---|---|---| ||Property|| ||2023|2022| ||R'000|F'000| |Less than one year|439|612| |Twn -five votre|2,663|151| |Greater than five years|1,147|| ||4,249|763| |Reconcilia
activities.|tio|n
ofne|t|incom|e/(expenditur|e)
to net cash inflow from|operating|| |---|---|---|---|---|---|---|---|---| ||||||||2023|2022| ||||||||6'000|E'000| |Net income/(expenditure)||||for|the reporting|period (as per the|(392)|10,383| |statement|of|financial|activities)|||||| |Adjustments||for:||||||| |Dividends|and interest||||||(722)|(73)| |Depreciation||charges|||||203|261| |Disposal||||||||13| |(Increase)|in|stocks|||||(10)|(40)| |Decrease|in|debtors|||||651|1,213| |Increase/(decrease)|||in|creditors|||1,032|(2,301)| |Net cash|used in operating||||activities||762|9,456| ## ## ## ||||Income|Income||2022| |---|---|---|---|---|---|---| ||||Unrestricted||Restricted|Total income| ||||K'000||f'000|K'000| |Individual|donors and legacies||15,652||354|16,006| |Community|and events||12,322||1|12,323| |Corporate|donors||2,101||368|2,469| |Major donors and charitable||trusts|586||1,085|1,671| |Donated goods and services|||73|||73| |Government
grant|||||2,409|2,409| ||||30,734||4,217|34,951| ||||Expenditure|on|raising funds|2022| ||||Direct costs||Support costs|Total costs| ||||K'000||E'000|K'000| |Individual|donors and legacies||5,004||699|5,703| |Community|and events||1,992||278|2,270| |Corporate|donors||665||93|758| |Major donors and charitable||trusts|390||54|444| |Trading|||200|||200| ||||8,251||1,124|9,375| |Note 5 - Charitable activities|||| |---|---|---|---| ||||2022| ||Direct|Support|Total costs| ||costs|costs|| ||f'000|R'000|8'000| |Research|1,308|220|1,528| |Support and influencing|2,536|1,003|3,539| |Awareness|8,553|2,065|10,618| ||12,397|3,288|15,685| ## |||||2022| |---|---|---|---|---| |||Raising funds|Charitable|Total costs| ||||activities|| |||E'000|6'000|F'000| |Staffand similar costs||579|1,693|2,272| |Supplies and|services|204|598|802| |Premises costs||290|849|1,139| |Depreciation||41|119|160| |Governance|costs|10|29|39| |||1,124|3,288|4,412| |Note 17 - Analysis
|ofgroup net assets|between funds|||| |---|---|---|---|---|---| |||General funds|Designated|Restricted|Total funds| ||||funds|funds|2022| |||F'000|R'000|F'000|F'000| |Fixed assets (Note 10and 11)|||322||322| |Research designated|funds||3,371||3,371| |Current assets||27,677||25,740|53,417| |Liabilities due within|one year|(4,203)||(7,531)|(11,734)| |Liabilities due after more than one year||(25)||(9,013)|(9,038)| |Net assets at 31 March||23,449|3,693|9,196|36,338| ## |||As at|Incoming|Outgoing|Transfers|As at| |---|---|---|---|---|---|---| |||1/04/2021||||31/03/2022| |||f.'000|6'000|8'000||6'000| |Restricted funds: Movember||||||| |Foundation||6,018||28||6,046| |Other restricted funds:||||||| |General research||1,263|1,415|||2,678| |IT architecture
project||123||(123)||| |Specialist Nurses Service||181|689|(710)||160| |NHS Funded
Projects|||1,899|(1,899)||| |Other restricted
funds||105|214|(7)||312| |Total other restricted|funds|1,672|4,217|(2,739)||3,150| |Total restricted funds||7,690|4,217|(2,711)||9,196| |Unrestricted
funds||13,509|31,226|(21,259)|(27)|23,449| |Designated
funds:||||||| |Fixed asset reserves||556||(261)|27|322| |Research designated|funds|4,200||(829)||3,371| |Total designated
funds||4,756||(1,090)|27|3,693| |Total unrestricted
funds||18,265|31,226|(22,349)||27,142| |Total funds||25,955|35,443|(25,060)||36,338| ## prostatacancaruKorg Prostate Cancer UK @ProstateUK prostat•conc•ruk in Pro8tat8 Can¢•r UK , PROSTATE CANCER UK